

Practice Trends and Attitudes of Medical Oncologists on New Therapies in Urothelial Carcinoma

Kristen M. Rosenthal, PhD¹; Matt D. Galsky, MD, FASCO²; Matthew I. Milowsky, MD³; Alexandra Howson, PhD⁴; Timothy A. Quill, PhD¹; and Kevin Obholz, PhD¹

¹Clinical Care Options, LLC, Reston, VA; ²Tisch Cancer Institute, Division of Hematology/Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY;

³University of North Carolina Department of Medicine, Division of Hematology/Oncology, Chapel Hill, NC; ⁴Thistle Editorial, LLC, Snoqualmie, WA

Background

Treatment options for patients with urothelial carcinoma (UC) have dramatically changed over the last 5 years, with the approval of various immune checkpoint inhibitors (ICIs), erdafitinib, and enfortumab vedotin. The goal of this study was to assess the impact and use of new therapeutic developments in clinical practice management of patients with UC as well as identify the current educational needs of healthcare providers who are involved in the care of patients with UC.

Methods

- 2-phase study was designed to determine current practice trends and specific challenges faced by clinicians
 - Phase 1: qualitative telephone interviews (3/25/19-4/5/19)
 - Phase 2: quantitative online survey (3/20/19-5/27/19)

- Participants were recruited via email and their responses were compared with those of experts, guideline recommendations, and regulatory approvals

Conclusions

- This study highlights the need for ongoing education on the optimal use of novel treatment strategies for patients with UC
- Only 40% of clinicians use regulatory guidance for appropriate PD-L1 testing
- ~ 50-60% of clinicians correctly selected SoC cisplatin-based CT for eligible patients with mUC
- For cisplatin-ineligible patients, ~ 60% of clinicians indicated use of ICI despite low PD-L1 expression
- 50%-60% of clinicians could identify the target of erdafitinib and ≤ 35% knew the MoA of investigational agents at the time of the survey



Copies of this poster obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without permission from ASCO® and the author of this poster.


Results

Participant Demographics


| Specialty, n (%) | Phase 1 (N = 30) | Phase 2 (N = 491) |
|----------------------------------|------------------|-------------------|
| Hem/Onc | 17 (57) | 100 (20) |
| Oncology | 8 (27) | 312 (64) |
| Urology | 5 (17) | 50 (10) |
| Other | -- | 29 (6) |
| Practice Setting, n (%) | | |
| Academic | 11 (37) | 137 (28) |
| Hospital/health system owned | -- | 143 (29) |
| Community-based practice | 9 (30) | 19 (4) |
| Private practice/physician owned | 7 (23) | 74 (15) |
| Community cancer center | 3 (10) | 109 (22) |
| Federal government owned | -- | 6 (1) |

Figure 1. Participants From Phase 2 Quantitative Interviews (N = 491)


A. Geographic Location



B. Years of Practice



C. Number of Patients With UC/Month



Use of Immune Checkpoint Inhibitors in Clinical Practice

Figure 2. Use of PD-L1 Biomarker Testing





Figure 3. Preferred Tx for Newly Diagnosed UC (US: n = 125; Ex-US: n = 258)



Knowledge of Novel Agents for Urothelial Carcinoma

Figure 4. Identifying Agent Targets/MoA (US: n = 132; Ex-US: n = 289)





Figure 5. Level of Evidence Needed to Implement Use of New Agents



Please contact Kristen Rosenthal, PhD, with questions or comments: krosenthal@clinicaloptions.com
Supported by an educational grant from Seattle Genetics and Astellas